Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: Interim analysis from the prospective GMMG-MM5 trial.
Merz M et al. Haematologica. 2015 Apr 3. pii: haematol.2015.124347. [Epub ahead of print].

Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT.
Grövdal M et al. Bone Marrow Transplant. 2015 Apr 13. doi: 10.1038/bmt.2015.39. [Epub ahead of print].

Use of biosimilar filgrastim compared with lenograstim in autologous haematopoietic stem-cell transplant and in sibling allogeneic transplant.
Uddin S et al. Ther Adv Hematol. 2015 Apr;6(2):53-60. doi: 10.1177/2040620714565962.

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Schey S et al. Br J Haematol. 2015 Apr 20. doi: 10.1111/bjh.13435. [Epub ahead of print].

Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.
Parrish C et al. Biol Blood Marrow Transplant. 2015 Apr 3. pii: S1083-8791(15)00226-8. doi: 10.1016/j.bbmt.2015.03.026. [Epub ahead of print].

Long-term Control in a Patient with Refractory Multiple Myeloma by Oral Cyclophosphamide and Dexamethasone.
Steiner N et al. Anticancer Res. 2015 Apr;35(4):2165-8.